SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Summary

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

Timeline

Start

2019-03-26

Primary completion

2023-05-04

Completion

2023-05-04

Outcome

Missed primary endpoint

release “SL-279252 clinical program, and not meeting a stringent efficacy threshold required to justify further development” shattucklabs.com ↗

release “We did not observe an overall response rate necessary to justify continued development in a very difficult PD-1 relapsed/refractory patient population” shattucklabs.com ↗

Publications

• Johnson M, Hong D, Brana I, Schoffski P, Galvao V, Rangwala F, Ma B, Hernandez R, Kamat A, Kato K, Schreiber TH, Pandite L, Siu LL. First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. Invest New Drugs. 2025 Apr;43(2):284-292. doi: 10.1007/s10637-025-01518-7. Epub 2025 Mar 5.

Drugs

Indications